Loading organizations...
Loading organizations...
Research and development of oncology and hepatitis B drugs.
Yangli Pharmaceutical has raised $14.1M across 1 funding round.
Yangli Pharmaceutical has raised $14.1M in total across 1 funding round.
Yangli Pharmaceutical has raised $14.1M in total across 1 funding round.
Yangli Pharmaceutical's investors include Chen Kan.
Yangli Pharmaceutical has raised $14.1M across 1 funding round. Most recently, it raised $14.1M Series B in November 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 13, 2025 | $14.1M Series B | Chen Kan |